Bausch + Lomb (BLCO) Q1 FY26 earnings call

Bausch + Lomb delivered robust Q1 FY26 results, showcasing strong revenue growth and significant adjusted EBITDA expansion, driven by structural changes and disciplined execution. The company is transitioning from launch to growth phase for key dry eye products and expects sequential improvement in the surgical business as its U.S. field force rebuild scales and new products launch. Management remains confident in achieving its 3-year targets for growth and margin expansion.